Bio-product sampling platforms

01Overview and value chain#

Markers EC: PDMA-compliant sample distribution & hub-services platforms | OECD: Bioeconomy policy & governance | Regulator: FDA (US)

Bio-product sampling platforms are a B2B services category that manages the distribution, tracking and Prescription Drug Marketing Act (PDMA) compliance of physician product samples for pharmaceutical and biotech companies, the specific logistics and compliance layer that gets a physical drug sample from manufacturer to prescriber legally and traceably. ConnectiveRx runs an access, launch and gross-to-net-focused patient-support business, recently launching ShieldRx with EagleForce to stop pharmacy misuse before claims are paid. EVERSANA operates as a leading 3PL and channel provider, having opened a new 358,000-square-foot distribution center with expanded cold-chain capability, an enhanced warehouse-management system and AI-powered robotics to support pharma sample and channel distribution. Cardinal Health’s Sonexus platform runs patient-support hub services, with 2026 research showing biopharma firms adopting hybrid hub models and AI tools to improve access and operational efficiency. TrialCard runs a specialty-pharmacy Bridge Program managing high-volume sample and patient-support operations day to day. Movianto (part of Walgreens Boots Alliance) provides market-ready healthcare logistics solutions for European pharmaceutical supply chains, including a 2026 UK partnership with the NHS. CareTria offers dedicated pharmaceutical samples-management services spanning distribution, fulfillment, field-representative audits and closeouts, and PDMA compliance guidance.

The key directions of bio-product sampling platforms are:

PDMA-compliant sample tracking: maintaining the chain-of-custody records the Prescription Drug Marketing Act requires for every physician sample distributed, from manufacturer through to the prescriber.
Field-representative sample audits and closeouts: auditing sales representatives’ sample inventories and closing out sample-distribution records to maintain compliance and prevent diversion.
Hub-services and patient-support platforms: integrated platforms combining sample distribution with broader patient-access services such as benefit verification and financial assistance.
Cold-chain sample distribution infrastructure: distribution centers and logistics networks capable of maintaining biologic and temperature-sensitive product samples through the distribution chain.

Sectoral value chain#

[Sample inventory allocation] ──> [Field-representative distribution] ──> [PDMA chain-of-custody tracking]
                                                                    │
                                                        (Field audit & closeout)
                                                                    │
              [Compliance reporting] <──── [Diversion/loss investigation] <─── [Prescriber sample receipt confirmation]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Sample inventory allocation	Allocating manufactured product samples to specific field representatives or distribution channels for physician delivery.	In: Manufactured sample stock, distribution plan. Out: Allocated sample inventory.
Field-representative distribution	Field representatives or logistics partners deliver samples directly to prescribers’ offices.	In: Allocated sample inventory. Out: Delivered physician samples.
PDMA chain-of-custody tracking	Recording each sample-distribution event to maintain the chain-of-custody record required under the Prescription Drug Marketing Act.	In: Delivered physician samples. Out: Chain-of-custody record.
Prescriber sample receipt confirmation	Obtaining the prescriber’s signed acknowledgment of sample receipt as required by PDMA.	In: Chain-of-custody record. Out: Signed receipt confirmation.
Field audit and closeout	Periodically auditing field representatives’ remaining sample inventory against distribution records to detect discrepancies.	In: Signed receipt confirmations, inventory records. Out: Audit findings, closed-out inventory.
Diversion/loss investigation and compliance reporting	Investigating any inventory discrepancy for possible diversion or loss, and reporting compliance status.	In: Audit findings. Out: Investigation outcome, compliance report.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

PDMA-compliant sample tracking: the specific chain-of-custody recordkeeping practice required under the Prescription Drug Marketing Act for every physician sample distributed.
Field-representative sample audits: systematic auditing of sales representatives’ sample inventories against distribution records to detect discrepancies and prevent diversion.
Hub-services platforms: integrated systems combining sample distribution with broader patient-access services such as benefit verification and financial assistance.

02US#

The United States hosts the largest concentration of dedicated sample-management platforms and hub-services providers, built specifically around PDMA compliance requirements unique to the US prescription-drug market.

ConnectiveRx’s access and launch business, EVERSANA’s expanded 3PL infrastructure, Cardinal Health Sonexus’ hybrid hub model, TrialCard’s Bridge Program, CareTria’s dedicated sample-management practice#

ConnectiveRx: runs an access, launch and gross-to-net-focused patient-support business, recently launching ShieldRx with EagleForce to stop pharmacy misuse before claims are paid.
EVERSANA: operates as a leading 3PL and channel provider, having opened a new 358,000-square-foot distribution center with expanded cold-chain capability and AI-powered robotics to support pharma sample and channel distribution.
Cardinal Health (Sonexus): runs patient-support hub services, with 2026 research showing biopharma firms adopting hybrid hub models and AI tools to improve access and operational efficiency.
TrialCard: runs a specialty-pharmacy Bridge Program managing high-volume sample and patient-support operations day to day.
CareTria: offers dedicated pharmaceutical samples-management services spanning distribution, fulfillment, field-representative audits and closeouts, and PDMA compliance guidance.

03CN#

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese sample-management platforms searched during this screen returned no confirming 2026 source, and China’s pharmaceutical marketing and sample-distribution rules differ structurally from the US Prescription Drug Marketing Act framework that defines this category.

No PDMA-equivalent sample-compliance vendor confirmed in China#

Structural difference: China regulates pharmaceutical marketing and sample distribution under its own framework rather than a PDMA-equivalent regime, so the specific “sample chain-of-custody platform” vendor category common in the US market does not map directly onto a confirmed Chinese counterpart.
Domestic gap: no Chinese-headquartered sample-management platform confirmed by a live 2026 source was found during this screen.

04EU#

Europe hosts major pan-European healthcare logistics operators handling pharmaceutical distribution, including sample-relevant cold-chain infrastructure, across fragmented national healthcare systems.

Movianto’s pan-European healthcare logistics network#

Movianto (Walgreens Boots Alliance): provides market-ready healthcare logistics solutions for European pharmaceutical supply chains, including a 2026 UK partnership with the NHS strengthening pharmaceutical logistics.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
ConnectiveRx	🇺🇸 USA	Access & launch patient-support platform	ShieldRx pharmacy-misuse prevention	commercial
EVERSANA Sample Fulfillment	🇺🇸 USA	3PL & channel distribution	358,000 sq ft facility, AI robotics	commercial
Cardinal Health (Sonexus)	🇺🇸 USA	Patient-support hub services	Hybrid hub + AI model	commercial
TrialCard	🇺🇸 USA	Specialty-pharmacy Bridge Program	High-volume sample operations	commercial
Movianto	🇩🇪 Germany	Pan-European healthcare logistics	NHS partnership (UK, 2026)	commercial
CareTria	🇺🇸 USA	Pharma samples-management platform	Field-rep audits, PDMA guidance	commercial

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The bio-product sampling platform technology stack combines PDMA-specific compliance tracking with AI-assisted logistics and integrated patient-support hub services:

PDMA-compliant sample tracking:
- CareTria and comparable platforms maintain the chain-of-custody recordkeeping required under the Prescription Drug Marketing Act for every physician sample distributed.
AI-powered distribution infrastructure:
- EVERSANA’s expanded distribution center combines cold-chain capability, an enhanced warehouse-management system and AI-powered robotics to support sample and broader channel distribution.
Hub-services and hybrid patient-support models:
- Cardinal Health’s Sonexus platform runs hybrid hub models combining human patient-support staff with AI tools to improve access and operational efficiency.

07Value chains and production pipelines#

Industrial pipeline for a PDMA-compliant physician sample distribution cycle#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sample inventory         │ ───> │ 2. Field-representative     │
│    allocation                   │      │    distribution                   │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Prescriber sample        │ <─── │ 3. PDMA chain-of-custody    │
│    receipt confirmation          │      │    tracking                       │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Field audit &            │ ───> │ 6. Diversion/loss           │
│    closeout                     │      │    investigation & reporting     │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for a PDMA-compliant physician sample distribution cycle

Stage 1: Sample inventory allocation

Manufactured product samples are allocated to specific field representatives or distribution channels for physician delivery.

Stage 2: Field-representative distribution

Field representatives or logistics partners deliver the allocated samples directly to prescribers’ offices.

Stage 3: PDMA chain-of-custody tracking

Each sample-distribution event is recorded to maintain the chain-of-custody record required under the Prescription Drug Marketing Act.

Stage 4: Prescriber sample receipt confirmation

The prescriber’s signed acknowledgment of sample receipt is obtained, as required by PDMA.

Stage 5: Field audit and closeout

Field representatives’ remaining sample inventory is periodically audited against distribution records to detect any discrepancies.

Stage 6: Diversion/loss investigation and compliance reporting

Any inventory discrepancy is investigated for possible diversion or loss, and the overall compliance status is reported.

Supplier	Region & tags
ConnectiveRx	US
EVERSANA	US
Cardinal Health (Sonexus)	US
TrialCard	US
Movianto	EU
CareTria	US

AI Recommendation

Key directions:

PDMA-compliant sample tracking — maintaining the chain-of-custody records the Prescription Drug Marketing Act requires for every physician sample distributed, from manufacturer through to the prescriber.
Field-representative sample audits and closeouts — auditing sales representatives’ sample inventories and closing out distribution records to maintain compliance and prevent diversion.
Hub-services and patient-support platforms — integrated platforms combining sample distribution with broader patient-access services such as benefit verification and financial assistance.
Cold-chain sample distribution infrastructure — distribution centers and logistics networks capable of maintaining biologic and temperature-sensitive product samples through the distribution chain.

Regulatory:

The Prescription Drug Marketing Act (PDMA) sets the specific US legal framework that defines this category — a physician sample is a legal drug product, and its distribution requires the same chain-of-custody discipline as any other regulated pharmaceutical transaction.
A missing or unsigned sample-receipt record can expose a manufacturer to compliance liability even if the sample itself was legitimately distributed, which is why field audits are treated as a distinct, recurring discipline rather than a one-time check.
Sample diversion (samples resold rather than given to patients) is the specific risk this entire compliance layer exists to prevent, distinct from counterfeiting or supply-chain theft.

Companies not in table: Owens & Minor and PSKW were searched as candidates; Owens & Minor was confirmed but is a general medical-products distributor rather than a dedicated sample-compliance platform and was dropped for category fit, while PSKW returned no confirming live source and was excluded rather than tabled from general knowledge.

Category boundary: this is distinct from general pharmaceutical 3PL and cold-chain logistics (see bio-customs-brokerage) — the differentiator here is PDMA-specific chain-of-custody and field-audit compliance for physician samples specifically, not general product distribution.

Processing note: China is not tabled because the category as defined is structurally tied to the US PDMA framework — Chinese pharmaceutical marketing operates under a different regulatory regime, so this is a genuine structural gap rather than a search failure.